Commission Delegated Regulation (EU) 2022/139 of 16 November 2021 supplementing Regulation (EU) 2016/429 of the European Parliament and of the Council as regards the management, storage and replacement of stocks of the Union antigen, vaccine and diagnostic reagent banks and the biosecurity, biosafety and bio-containment requirements for the operation of those banks (Text with EEA relevance)
Commission Delegated Regulation (EU) 2022/139of 16 November 2021supplementing Regulation (EU) 2016/429 of the European Parliament and of the Council as regards the management, storage and replacement of stocks of the Union antigen, vaccine and diagnostic reagent banks and the biosecurity, biosafety and bio-containment requirements for the operation of those banks(Text with EEA relevance)THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health ("Animal Health Law")OJ L 84, 31.3.2016, p. 1., and in particular Article 48(3) thereof,Whereas:(1)Regulation (EU) 2016/429 lays down rules for the prevention and control of diseases which are transmissible to animals or humans, including rules for the establishment and management of the Union antigen, vaccine and diagnostic reagent banks. In accordance with Article 48(1) of that Regulation, the Commission may establish and be responsible for managing the Union antigen, vaccine and diagnostic reagent banks for the storage and replacement of stocks of antigens, vaccines, vaccine master seed-stocks and diagnostic reagents for the listed diseases referred to in Article 9(1), point (a), thereof, in respect of which vaccination is not prohibited by a delegated act adopted pursuant to Article 47 thereof. The establishment of Union antigen, vaccine and diagnostic reagent banks, in accordance with that Regulation, would promote the attainment of the Union’s animal health objectives by permitting a quick and effective response when the resources of those banks are required in the event of the occurrence of a category A disease, as defined and categorised by Commission Implementing Regulation (EU) 2018/1882Commission Implementing Regulation (EU) 2018/1882 of 3 December 2018 on the application of certain disease prevention and control rules to categories of listed diseases and establishing a list of species and groups of species posing a considerable risk for the spread of those listed diseases (OJ L 308, 4.12.2018, p. 21)., and would represent an efficient use of limited resources.(2)Furthermore, Article 47(1) of Regulation (EU) 2016/429 empowers the Commission to adopt delegated acts laying down rules concerning the use of veterinary medicinal products, including vaccines, for the purpose of the prevention and control of listed diseases in terrestrial animals. Those delegeted acts will specify the category A diseases which could be prevented or controlled by use of vaccines in kept and wild terrestrial animals. Therefore, this Regulation should supplement the rules laid down in Part III of Regulation (EU) 2016/429, and provide for the establishment of Union antigen and vaccine banks for category A diseases, for which vaccination is not prohibited, and for the establishment of Union diagnostic reagent banks for category A diseases covered by those delegated acts that are to be adopted pursuant to Article 47(1) of Regulation (EU) 2016/429. In addition, Commission Implementing Regulation (EU) 2022/140Commission Implementing Regulation (EU) 2022/140 of 16 November 2021 laying down rules for the application of Regulation (EU) 2016/429 of the European Parliament and the Council with regard to the Union antigen, vaccine and diagnostic reagent banks (See page 11 of this Official Journal). provides a list of category A diseases for which the Union antigen, vaccine and diagnostic reagent banks are established and maintained.(3)The Commission should purchase the antigens, vaccines and diagnostic reagents to be supplied to the Union antigen, vaccine and diagnostic reagent banks and should cover the expenses for the storage of the antigens, vaccines and diagnostic reagents therein. In order to establish and maintain those banks, the Commission should conclude appropriate contracts with selected manufacturers for the purchase, supply, storage and replacement of antigens, vaccines or diagnostic reagents. For that purpose, a procurement procedure should be carried out in accordance with the rules laid down in Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the CouncilRegulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012 (OJ L 193, 30.7.2018, p. 1)..(4)In addition, it is necessary to provide for a "hybrid" mechanism, corresponding to framework supply contracts between the Commission and selected manufacturers to provide vaccines or diagnosic reagents to the Member States, third countries or territories, when requested by the Commission. Those Union antigen, vaccine and diagnostic reagents banks should be virtual given that the Commission does not keep any physical stocks, but rather calls upon a framework supply contract with one or more vaccine manufacturers for the release, shipment and delivery of the necessary vaccines or diagnostic reagents. The framework supply contracts may need to cover leasing costs. The terms of the framework supply contracts should allow the Commission to immediately require the manufacturers to release, ship and deliver vaccines or diagnostic reagents to a Member State, third country or territory that has been granted access to the Union antigen and vaccine banks. The availability of rolling stocks of vaccines or diagnostic reagents coupled with a fast decision-making process within the Commission would guarantee a service that rapidly provides high quality vaccines or diagnosic reagents.(5)In addition to framework supply contracts, the Commission should, in the framework of a grant agreement, be permitted to include the stockpiling of essential diagnostic reagents in the annual or multiannual work programmes of the European Union reference laboratories designated for the relevant diseases in accordance with Article 93(1) of Regulation (EU) 2017/625 of the European Parliament and of the CouncilRegulation (EU) 2017/625 of the European Parliament and of the Council of 15 March 2017 on official controls and other official activities performed to ensure the application of food and feed law, rules on animal health and welfare, plant health and plant protection products, amending Regulations (EC) No 999/2001, (EC) No 396/2005, (EC) No 1069/2009, (EC) No 1107/2009, (EU) No 1151/2012, (EU) No 652/2014, (EU) 2016/429 and (EU) 2016/2031 of the European Parliament and of the Council, Council Regulations (EC) No 1/2005 and (EC) No 1099/2009 and Council Directives 98/58/EC, 1999/74/EC, 2007/43/EC, 2008/119/EC and 2008/120/EC, and repealing Regulations (EC) No 854/2004 and (EC) No 882/2004 of the European Parliament and of the Council, Council Directives 89/608/EEC, 89/662/EEC, 90/425/EEC, 91/496/EEC, 96/23/EC, 96/93/EC and 97/78/EC and Council Decision 92/438/EEC (Official Controls Regulation) (OJ L 95, 7.4.2017, p. 1).. Such Union diagnostic reagent banks are appropriate for the tasks of the European Union reference laboratories referred to in Article 94(2) of Regulation (EU) 2017/625, and in particular point (f), point k(iii) and point (l) thereof. The European Union reference laboratories have the necessary experience in the quality testing, storage, timely renewal and disposal of diagnostic reagents, and it would be an appropriate use of the infrastructures already in place. The annual or multiannual work programmes of the European Union reference laboratories are established in conformity with the objectives and priorities of the relevant work programmes referred to in Article 3(2), point (e), of Regulation (EU) 2021/690 of the European Parliament and of the CouncilRegulation (EU) 2021/690 of the European Parliament and of the Council of 28 April 2021 establishing a programme for the internal market, competitiveness of enterprises, including small and medium-sized enterprises, the area of plants, animals, food and feed, and European statistics (Single Market Programme) and repealing Regulations (EU) No 99/2013, (EU) No 1287/2013, (EU) No 254/2014 and (EU) No 652/2014 (OJ L 153, 3.5.2021, p. 1). and adopted by the Commission, and thus provide the opportunity for regular review of the measures.(6)When deciding on the principles for selecting strains and variations of antigens and vaccines to be supplied to the Union antigen, vaccine and diagnostic reagent banks in order to ensure sufficient quantities, the required quality and the appropriate types of stocks in those banks, the Commission should take account of the advice of experts, including experts from institutions such as the European Union reference laboratories, or any other international standard setting bodies relevant to the disease in question, including the European Commission for the Control of Foot-and-Mouth Disease (EuFMD).(7)The contract concluded with a selected manufacturer should guarantee appropriate conditions for the destruction and safe disposal of any unused antigen, vaccine or diagnostic reagent stored in the Union antigen, vaccine and diagnostic reagent banks after the expiry of its validity period. In cases where an antigen is supplied to a Union antigen bank and remains in that bank after the expiry of its validity period, the contract may lay down conditions for a buy-back of the antigen by the contracted manufacturer.(8)Biosecurity, biosafety and bio-containment requirements for the operation of the Union antigen, vaccine and diagnostic reagent banks should be established in this Regulation, taking into account the recommendations of Chapter 1.1.4 "Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities" of the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals of the World Organisation for Animal Health (OIE), Edition 2021. The antigens, vaccines and diagnostic reagents should also comply with recognised quality standards, such as those laid down in Chapter 1.1.5 "Quality management in veterinary testing laboratories", in Chapter 1.1.8 "Principles of veterinary vaccine production", in Chapter 1.1.10 "Vaccine banks", and in disease-specific chapters of that Manual.(9)It is important to verify compliance with the biosecurity, biosafety and bio-containment requirements of operations carried out by the Union antigen, vaccine and diagnostic reagent banks through controls. Therefore, in addition to regular and risk-based controls of manufactures and laboratories carried out by the competent authorities of the Member States, the Commission should perform controls at the Union antigen, vaccine and diagnostic reagent banks to ensure continuous compliance with the relevant standards agreed to in the contracts concluded between the Commission and the manufacturers. Those inspections should be carried out in accordance with Regulation (EU) 2017/625.(10)Prior to the date of application of Regulation (EU) 2016/429 on 21 April 2021, the Commission already established and maintained the following Union banks: the foot-and-mouth disease antigen and vaccine bank in accordance with Council Decision 91/666/EECCouncil Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and-mouth disease vaccines (OJ L 368, 31.12.1991, p. 21). and with Article 80(1) of Council Directive 2003/85/ECCouncil Directive 2003/85/EC of 29 September 2003 on Community measures for the control of foot-and-mouth disease repealing Directive 85/511/EEC and Decisions 89/531/EEC and 91/665/EEC and amending Directive 92/46/EEC (OJ L 306, 22.11.2003, p. 1).; the classical swine fever vaccine bank in accordance with Article 18(2) of Council Directive 2001/89/ECCouncil Directive 2001/89/EC of 23 October 2001 on Community measures for the control of classical swine fever (OJ L 316, 1.12.2001, p. 5). and with Commission Decision 2007/682/ECCommission Decision 2007/682/EC of 18 October 2007 on the renewal of the Community stocks of live attenuated vaccine against classical swine fever (OJ L 281, 25.10.2007, p. 25).; and the lumpy skin disease vaccine bank, peste des petits ruminants vaccine bank and sheep pox and goat pox vaccine bank in accordance with Article 6(5) of Regulation (EU) No 652/2014 of the European Parliament and of the CouncilRegulation (EU) No 652/2014 of the European Parliament and of the Council of 15 May 2014 laying down provisions for the management of expenditure relating to the food chain, animal health and animal welfare, and relating to plant health and plant reproductive material, amending Council Directives 98/56/EC, 2000/29/EC and 2008/90/EC, Regulations (EC) No 178/2002, (EC) No 882/2004 and (EC) No 396/2005 of the European Parliament and of the Council, Directive 2009/128/EC of the European Parliament and of the Council and Regulation (EC) No 1107/2009 of the European Parliament and of the Council and repealing Council Decisions 66/399/EEC, 76/894/EEC and 2009/470/EC (OJ L 189, 27.6.2014, p. 1).. Directives 2001/89/EC and 2003/85/EC and Decision 91/666/EEC are repealed by Regulation (EU) 2016/429 with effect from 21 April 2021. In addition, Commission Delegated Regulation (EU) 2020/687Commission Delegated Regulation (EU) 2020/687 of 17 December 2019 supplementing Regulation (EU) 2016/429 of the European Parliament and the Council, as regards rules for the prevention and control of certain listed diseases (OJ L 174, 3.6.2020, p. 64). provides that Directives 2001/89/EC and 2003/85/EC, as well as the acts adopted on the basis thereof, including Decision 2007/682/EC, are to cease to apply with effect from 21 April 2021. Regulation (EU) No 652/2014 is repealed by Regulation (EU) 2021/690 of the European Parliament and of the Council with effect from 1 January 2021. Article 24(1) of Regulation (EU) 2021/690 ensures that Union financial contributions for the establishment of those Union banks awarded under Article 6(5) of Regulation (EU) No 652/2014 continue to be applicable as of 1 January 2021. Therefore, the Union banks established based on those repealed acts should be maintained after the date of application of this Regulation until the date of expiry of the relevant contracts.(11)In order to ensure the time needed for the establishment of the Union antigen, vaccine and diagnostic reagent banks based on the new rules, this Regulation should apply from 1 May 2022,HAS ADOPTED THIS REGULATION: